Core Viewpoint - Jiuyuan Gene (02566) saw a nearly 24% increase in stock price, attributed to the upcoming board meeting to approve mid-term performance and the potential of its biosimilar drug Semaglutide in the domestic market [1] Company Developments - Jiuyuan Gene's stock rose by 23.72% to HKD 15.28, with a trading volume of HKD 41.215 million [1] - The company plans to hold a board meeting on August 18 to approve its mid-term performance [1] - Jiuyuan Gene is focusing on the metabolic field, particularly with its potential first domestic biosimilar of Semaglutide [1] Market Strategy - The company aims to leverage its first-mover advantage in the hospital market and expand accessibility through pharmacy networks and strategic partnerships with e-commerce platforms [1] - Jiuyuan Gene has granted overseas rights for Semaglutide to other domestic pharmaceutical companies, including a unique licensing agreement with Sinovac Biotech for major Latin American countries [1] - A product licensing agreement with Fosun Pharma allows them exclusive rights for clinical development, registration, and commercialization of Semaglutide and other products in the Middle East, North Africa, sub-Saharan Africa, and parts of ASEAN countries [1] - New drug applications for Semaglutide are expected to be submitted to Brazil and Saudi Arabia by 2025 [1]
九源基因尾盘涨近24% 将于下周一发布业绩 预计年内向巴西等递交司美格鲁肽新药申请